Will the CDC weaken vaccine recommendation against _____ for children and adolescents in 2026?

This event predicts whether the U.S. Centers for Disease Control and Prevention (CDC), including adoption by the Advisory Committee on Immunization Practices (ACIP), will weaken its official recommendations for the vaccines mentioned in the listed markets for children and adolescents at any time during 2026 (the “Market Period”), compared to guidance in effect at the start of 2026. The Primary Designated Source (PDS) is official CDC/ACIP guidance published in the Morbidity and Mortality Weekly Report (MMWR), the CDC Child & Adolescent Immunization Schedule, and CDC/ACIP vaccine pages.

A weakening qualifies only if CDC/ACIP adopts and publishes an official change that (i) narrows eligibility via age or indication restrictions, or (ii) expands cautions/precautions or adds new contraindications specific to the listed vaccines. Votes or announcements in 2026 that are formally adopted and reflected in official CDC/ACIP materials count; if adopted in 2026 but stated to take effect later, this still qualifies. Changes that maintain or make guidance more permissive do not qualify.

These markets will be resolved according to the substantive policy outcome and market intent, not minor formatting or web-editing artifacts. If official materials are unavailable, ambiguous, or materially delayed, Futuur may consult additional CDC/ACIP records to confirm adoption; if no fair determination is possible, Futuur may cancel the markets with a public explanation.